NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
Provided By GlobeNewswire
Last update: Nov 18, 2024
– Met primary endpoint with LDL-C mean reduction versus placebo of 36.3% at day 84 and 41.5% at day 365 –
– Lp(a) mean reduction versus placebo of 45.9% at day 84 and 54.3% at day 365 –
Read more at globenewswire.com18.2
-0.29 (-1.57%)
NASDAQ:NAMSW (6/18/2025, 8:11:04 PM)
9.77
+0.95 (+10.77%)
Find more stocks in the Stock Screener
NAMS Latest News and Analysis
11 days ago - ChartmillGet insights into the top gainers and losers of Monday's pre-market session.The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
